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While platelets are the cellular mediators of thrombosis, platelets are also immune cells. 
Platelets interact both directly and indirectly with other cells, impacting immune cell activation 
and differentiation, as well as all phases of the immune response.  Megakaryocytes (Mks) are 
the cell source of circulating platelets and until recently Mks were typically only considered as 
bone marrow (BM) resident cells.  However, platelet producing Mks also reside in the lung, and 
lung Mks express increased levels of immune molecules compared to BM Mks.  We therefore 
sought to define the immune functions of lung Mks.  Using single cell RNA-Seq of BM and lung 
myeloid enriched cells, we found that lung Mks (MkL) have gene expression patterns that are 
similar to antigen presenting cells (APC). This was confirmed using imaging and conventional 
flow cytometry.  The immune phenotype of Mks is plastic and driven by the tissue immune 
environment as evidenced by BM Mks having a MkL like phenotype under the influence of 
pathogen receptor challenge and lung associated immune molecules such as IL-33.   Our in 
vitro and in vivo assays demonstrated that MkL internalized and processed both antigenic 
proteins and bacterial pathogens.  Furthermore, MkL induce CD4+ T cell activation in a MHC II 
dependent manner both in vitro and in vivo.  These data indicate that Mks in the lung have key 





Platelets are commonly described as megakaryocyte (Mk) derived cellular mediators of 
thrombosis.  Mk differentiation and platelet production have been extensively studied in the bone 
marrow (BM) environment, but recent research has expanded our prior limited view of both 
platelet origins and functions. Platelets are increasingly appreciated as having diverse 
inflammatory and immune regulatory roles (1), and despite studies going back to 1893 by Aschoff 
demonstrating that Mks reside in the lungs, lung Mks were only recently shown to be a significant 
source of circulating platelets (2-6). These novel emerging concepts of platelet functions and 
origins are rapidly re-shaping how we view platelets in both health and disease.  
Upon activation, platelets either express or secrete abundant inflammatory and immune 
molecules that recruit and activate leukocytes, both at sites of platelet deposition and systemically 
(7-12).  Platelets and platelet derived immune mediators contribute to the initiation or acceleration 
of inflammatory diseases such as atherosclerosis and asthma, as well as responses to bacterial 
and viral infection (13-15).  The large number of circulating platelets, and the diversity of their 
inflammatory molecules, including platelet factor 4 (PF4), CCL5, CD154, and transforming growth 
factor beta (TGF-β), give platelets important and under-appreciated immune functions relevant in 
many disease contexts (2, 11, 16-18). We have shown that platelets initiate, accelerate, and 
regulate of all phases of the immune responses, including platelet induction of an acute phase 
response (19), regulation of monocyte trafficking and differentiation (17), induction and 
maintenance of T helper cell differentiation (20), and platelets processing and presentation of 
antigen to CD8+ T cells (21).  Others have also demonstrated that Mks can cross present antigen 
in vitro (22). These studies, and those by many other labs, have demonstrated a central role for 
platelets and Mks in both innate and acquired immune responses.   
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Recent studies demonstrated that intravascular lung Mks produce circulating platelets and 
also identified non-platelet producing, sessile Mks in lung interstitial tissue (2). Bulk RNA-Seq 
data compared BM and lung Mks and found that lung Mks were enriched with mRNAs associated 
with immune regulatory functions, including mRNA for many immunoreceptors, chemokines, and 
cytokines (2).  The role of Mks as immune regulatory cells is poorly understood in general, but 
particularly so with lung Mks.  Lung Mks increase in number during pulmonary and cardiovascular 
diseases, further suggesting that lung Mks may be dynamic and responsive to inflammatory states 
(23).   
Lungs and BM are very different tissue environments.  Compared to the lung, the BM 
faces few pathogen challenges, is relatively hypoxic, and is an immune suppressive environment. 
In contrast, the lung has a microbiome, high O2, and the lung tissue environment is primed to 
induce immune cell activation (24-26).  Cells in the lung, such as airway epithelial cells (AEC), 
produce cytokines in response to pathogen or immune challenge that regulate immune cell 
differentiation, including the maturation of lung dendritic cells (27).  Like all hematopoietic derived 
immune cells, Mks come from hematopoietic stem cells (HSCs) and develop under the influence 
of thrombopoietin (TPO).  Because Mks have only been studied in the immune quiescent BM 
environment, it is not known whether Mks in other tissues have a different immune functional 
phenotype.  Our data now demonstrate that lung and BM Mks have distinct immune phenotypes 
and functions; lung Mks secrete inflammatory cytokines and express molecules that are similar 
to antigen presenting cells (APCs), and lung Mks process live intact bacteria and present bacteria-
derived antigen to CD4+ T cells both in vitro and in vivo.  Our in vivo data suggest that lung Mks 
have important roles in the early activation of T cell responses to pulmonary pathogen challenge, 
identifying a novel immune regulatory role for lung Mks.  
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Results 
To verify the presence and distribution of Mks in the lung, immunohistochemistry (IHC) 
with anti-CD42c antibody was performed on lung tissue isolated from wild-type (WT) and Mk 
deficient thrombopoietin receptor knockout (TPOR-/-)(28) mice as a negative control.  Macaque 
monkey lungs were also immunostained with anti-CD41 antibody.  IHC demonstrated that Mks 
were diffusely distributed throughout both WT mouse and primate lungs (Fig 1A).   Unlike BM 
Mks, lung Mks resembled leukocytes and were smaller than BM Mks with a primarily 2N ploidy 
distribution (Fig 1B), potentially explaining why the presence of lung Mks has been largely 
overlooked.  Using collagen digested lung tissue and flow cytometry to assess Mk and DC 
numbers, Mks were approximately 2-3% of the total lung cell population, versus lung DCs 
(CD103+, CD11b+), which were approximately 6-7% (Fig 1C).  To gain a more complete analysis 
of gene expression differences between BM and lung Mks in relation to other hematopoietic 
cells in each tissue, we performed single cell RNA sequencing (scRNA-seq) and integrated 
cluster analysis on myeloid enriched BM and lung cell isolates.  Mks identified by common Mk 
markers in the BM and lungs clustered as genetically distinct populations, with lung Mks 
clustering more closely to both BM and lung DCs (Fig 1D).  Further gene expression analysis 
indicated that lung Mks expressed numerous genes typical of immune related molecules, 
including many associated with DCs (Fig 1E and Supplementary S1-S3).  These data were 
validated in part using imaging flow cytometry to rule out the potential for analyzing myeloid 
cells with adherent platelets.  Lung Mks, but not BM Mks, expressed MHC II and DC markers 
such as CD11c (Fig 2A and Supplementary S4).  Mks were further phenotyped for APC-like 
markers including MHC II, CD80, CD40, ICAM-1, LFA-1, and CCR7 (Fig 2B and Supplementary 
S5), which were all expressed at higher levels on lung Mks relative to BM Mks.  Additionally, 
macaque primate lung Mks had a similar APC-like, immune phenotype as mouse lung Mks (Fig 
2C and Supplementary S6).   Taken together, these data indicate that unlike BM Mks, lung Mks, 
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that we now term MkL, have an immune phenotype with several characteristics typical of an 
APC.   
Lungs and BM are very different tissue environments; BM is sterile and hypoxic, while 
lungs face constant pathogen/antigen challenges and high O2 exposure.  Newborn post-natal day 
0 (P0) mouse lungs have not had prolonged O2 exposure or antigenic challenges and P0 lungs 
have an immature immune cell population (25). To begin to determine whether the tissue 
environment influences MkL differentiation, we compared P0 neonatal and adult mouse lung Mks.  
MHC II and ICAM1 were each expressed at much higher levels on adult compared P0 mouse 
MkL, suggesting that the Mk immune phenotype may be post-natal environmentally regulated (Fig 
3A).  To demonstrate the potential for Mk immune plasticity, BM Mks were isolated using a 
negative selection protocol (purity of isolation protocol confirmed by imaging flow cytometry, 
Supplementary S7), BM Mks were fluorescently labeled and then delivered via an oropharyngeal 
(OP) route to recipient mice (control mice given buffer only via OP route).  Two days later 
transferred cells were recovered and assessed by flow cytometry.  Transferred BM Mks acquired 
a MkL immune phenotype in the lung (Fig 3B) indicating that the lung environment may dictate 
MkL immune differentiation. 
To explore a potential role for O2 in MkL immune differentiation, isolated BM Mks were 
exposed to hypoxic or normoxic (5% or 21% O2) conditions in vitro for 48 hrs.  MHC II expression 
was not changed by incubation in hypoxic conditions indicating that O2 is unlikely to regulate Mk 
immune differentiation (Supplementary S8). To investigate whether pathogen associated and/or 
cytokine mediated stimulation induced BM Mks to acquire a MkL-like phenotype, BM Mks were 
isolated and stimulated with pathogen receptor agonists or with interferon gamma (IFN).  LPS, 
IFN, and CpG each increased BM Mk MHC II expression, further demonstrating BM Mk immune 
plasticity (Figure 3C, Supplementary S9).  The cellular composition and cytokine milieu also differ 
between lungs and BM.  Tissue-resident cells in the lung, such as airway epithelial cells (AEC), 
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secrete cytokines that promote DC maturation, including IL-33, IL-13, and TSLP (29).  BM Mks 
incubated with IL-33, either alone or with the other lung DC maturation cytokines, increased MHC 
II and ICAM1 expression (Fig 3D).  Together these data demonstrate that the Mk phenotype is 
‘plastic’ and can be altered by immune stimuli.  
To explore whether IL-33 regulates MkL immune differentiation in vivo, mice were treated 
with Mk-lineage depleting antibody or control IgG to deplete lung Mks (Supplementary Fig S10). 
24 hours later mice were treated with ST2/IL-33R-Fc chimera protein (ST2-Fc) to block IL-33 
during the MkL recovery. Recovered MkL were then assessed on d4 post-depletion and found to 
express higher levels of MHC II compared to control mouse MkL (Fig 3E). However, blocking IL-
33 greatly reduced MHC II expression on the recovering MkL (Fig 3E).  To further demonstrate a 
potential role for IL-33 in lung MkL immune differentiation, neonatal mice were treated with control 
IgG or ST2-Fc on P1 and P4, and MkL immune phenotype determined on day P7.  Blocking IL-33 
reduced MkL MHC II and ICAM1 (Fig 3F).  Taken together, these data suggest an important role 
for IL-33 in MkL immune differentiation.   
We next asked whether primary MkL and BM Mks differ in their responses to immune 
stimuli.  To begin to address this question, we isolated MkL and BM Mks and Mks were stimulated 
overnight with LPS (10 ng/mL) or control buffer.  As a control, BM derived dendritic cells (BMDC) 
were prepared and also treated with buffer or LPS. A cytokine membrane array was performed 
on the supernatants. Compared to BM Mks, MkL secreted more immune molecules that were 
similar to the molecules secreted by LPS challenged BMDC (Fig. 4A).  These data were confirmed 
by measuring KC secretion which was found to be much higher in the supernatant of LPS 
stimulated MkL than BM Mks (Fig 4B).   
For a cell to function as an APC it must internalize and process an antigen in order to 
present the antigen to CD4+ T cells. To determine whether Mks process antigen, we cultured 
primary BM Mks and MkL with DQ-Ovalbumin (Ova, 200 µg/mL) and cell fluorescence was 
determined by flow cytometry 30 minutes later as a measure of Ova processing (DQ-Ova only 
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fluorescent following cleavage).  BM and lung Mks similarly processed Ova antigen in vitro (Fig 
4C).   To determine whether MkL acquire and process antigen in vivo, PF4 reporter mice (Pf4Cre-
Rosa26-LSL-tdTomato mice) were challenged with LPS (0.5 mg/kg) then DQ-Ova was delivered 
via an oropharyngeal (OP) route and the lungs live imaged for 80 minutes.  PF4+ cells acquired 
and processed DQ-Ova (Fig 4D and online video).  DQ-Ova was also noted in MkL 24 hrs after 
OP delivery (Fig 4E).  To compare the ability of MkL and BM Mks to take up bacteria, isolated Mks 
were co-cultured with live GFP+ E. coli for 30 minutes and imaging flow cytometry used to 
measure intracellular bacteria.  While MkL and BM Mks both phagocytosed E. coli, MkL 
internalized more E. coli (Fig 4F).  GFP+ E. coli were also delivered to mice via an OP route and 
3 hrs later the number of GFP+ MkL and DCs were similar (Fig 4G).  These data demonstrate that 
MkL are phagocytic and can acquire inhaled antigens and pathogens.  
Because MkL cells expressed MHC II and acquired antigen, we next asked whether MkL 
present antigen to CD4+ T cells in vitro. Isolated MkL and BMDCs were LPS stimulated, incubated 
with Ova and co-cultured with OTII T cells that recognize Ova presented in the context of MHC II 
for 3 days.  MkL activated OTII T cells in an Ova dependent manner (Fig 5A).  To begin to 
determine whether MkL present antigen in vivo, OTII T cells were transferred to WT and TPOR-/- 
mice (TPOR-/- mice have greatly reduced numbers of Mks and circulating platelets (28)).  24 hrs 
after OTII cells were infused, mice were given Ova expressing E. coli (E. coliOva) via an OP route.  
OTII cell activation in the lungs and mediastinal lymph nodes (mLN) was then determined on d3 
by flow cytometry.  Infected WT and TPOR-/- mice had similar post-infection weight loss, indicating 
similar infections (Supplementary S11), however, OTII T cells in the lungs and mLN of WT infected 
mice were more activated compared to those in TPOR-/- mice (Fig 5B and Supplementary S12).  
These data indicate that MkL may regulate CD4+ T cell responses to lung infection.   
Because the TPOR-/- mice also have greatly reduced platelet counts, we could not rule out 
a platelet mediated OTII response mechanism.  Therefore, we next asked whether MkL can 
directly present antigen to CD4+ T cells in a MHC II dependent manner.  MkL were isolated from 
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WT and complete MHC II-/- mice and co-cultured with OTII T cells and Ova.  Naïve OTII T cell 
activation was assessed 3 days later and found to be greatly reduced with MHC II-/- MkL co-
incubation (Fig 5C).  In separate experiment, OTII T cells were co-cultured with WT MkL, MHC II-
/- MkL, or BMDC and Ova for 8d and IL-2 production determined by ELISA. IL-2 increased in WT, 
but not MHC II-/- MkL and BMDC co-cultures (Fig 5D).  These data indicate that MkL activate CD4+ 
T cells in a MHC II dependent manner.   
To more specifically determine whether MkL mediated lung CD4+ T cell responses are 
MHC II dependent, we made PF4cre-MHC IIflox/flox (Mk-MHC II-/-) mice. WT and Mk-MHC II-/- mice 
had similar immune cell development and platelet activation (Supplementary S13-17), and MkL, 
but not DCs, had reduced MHC II expression (Supplementary S18).  WT and Mk-MHC II-/- mice 
each received OTII T cell transfer and E. coliOva infection (Supplementary S19).  On d3 post-
infection, OTII T cells in WT mouse lungs had increased CD25 and more proliferation compared 
to Mk-MHC II-/- mice (Fig 5E).  OTII cells in mLNs were similar in both WT and Mk-MHC II-/- mice 
(Supplementary S20), demonstrating that CD4+ T cell activation in the lung is at least in part Mk 





Our data indicate that MkL have novel and prior unknown immune regulatory roles, 
including in vitro and in vivo APC-like functions.  Our scRNA-seq data indicated that MkL and BM 
Mks are genetically distinct populations with MkL expressing a number of key genes in common 
with DCs.  We have also demonstrated that MkL immune phenotype is at least in part shaped by 
their tissue environment, as the lung is continuously exposed to pathogens and lung cells secrete 
cytokines, such as IL-33, that contribute to MkL immune differentiation.  We demonstrate the ability 
of MkL to mediate host responses to pathogenic challenge suggesting that MkL and BM Mks have 
distinct immune functions and that MkL may have roles in pulmonary immune responses, including 
in common diseases such as asthma and allergy, lung infections, and pulmonary hypertension, 
providing potential new avenues for future therapeutic development. 
The developmental origin of lung Mks is not yet clear.  There are HSCs in the lung and 
lung Mks can re-populate the BM and vice versa (2).  When combined with our current data, this 
suggests that similar to other immune cells, the tissue environment, rather than an inherent 
genetic program during site specific development, has a major effect on their immune 
phenotype.  However, at this point it is unclear whether lung Mks are primarily derived from lung 
HSCs or are seeded from a bone marrow source, and whether the limited ploidy of lung Mks is 
directly associated with their immune differentiation.  MHC II is expressed on burst-colony-
forming-unit Mk progenitors, but its expression is lost with Mk maturation typified by increased 
Mk ploidy (30).  Without the maturation stimuli found in the BM, lung Mks may be ‘less mature’ 
and retain the expression of MHC II.   
 Our studies may lead to a better understanding of the pathogenesis of lung diseases ranging 
from infectious pneumonias, to asthma, and pulmonary hypertension.  While DCs clearly have a 
major role in CD4+ T cell responses, therapies solely aimed at DCs may be missing other relevant 
immune activating cells, including Mks, as our data indicates that a reduction in Mk MHC II in the 
lung results in decreased CD4+ T cell activation in an antigen specific manner.  TPOR-/- mice 
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deficient in Mks and platelets had only limited CD4+ T cell activation.  This implies that lung Mks 
or circulating platelets support CD4+ T cell responses to lung pathogens by mechanisms beyond 
directly presenting antigen.  This likely includes the secretion of lung Mk cytokines or chemokines 
that help to drive immune responses and development beyond direct antigen presentation.  
Although we have focused on this intriguing T cell activating function for lung Mks, they are likely 
to have important roles in all phases of lung immune responses.  MkL may also be important in 
immune homeostasis, as we have shown that platelets maintain both basal T helper cell and 
monocyte immune phenotypes.  MkL may therefore have key roles in lung immune quiescence in 
healthy conditions that remain to be discerned.  
  These studies demonstrate an important immune function for Mks in the lung and represent 
a very novel concept - MkL can internalize, process, and present antigen to CD4+ T cells.  While 
more work needs to be done to determine the disease relevance of these studies and the 





Mice.  All experiments were performed using institutional animal care and use committee 
(IACUC) approved protocols.  All mice used in our studies were on a C57BL/6J background.  
Mice that were not bred in-house were purchased from Jackson Labs.  All mice used were 8 to 
12 weeks of age and a mix of males and females in our in vivo experiments. I-AB-flox mice 
(stock number 003584) and PF4-cre mice were purchased from Jackson Labs.  Thrombopoietin 
receptor knockout (TPOR-/-) were used in prior studies by our laboratory(17, 20).  
 
Single cell suspension for cell culture, ImageStream flow cytometry, flow cytometry, and 
scRNA-seq.  Whole lungs were removed and put into complete DMEM with 1 mg/mL of 
collagenase type II (Fisher Scientific; Catalog #NC9693955). Complete DMEM consisted of 10% 
FBS (Invitrogen), Penicillin/streptomycin (Invitrogen; Cat #15-140-122), vitamins (Invitrogen; Cat 
#11120052), Glutamax (Invitrogen; Cat #10566016), non-essential amino acids (Invitrogen; Cat 
#11140050), and sodium pyruvate (Invitrogen; Cat #11-360-070).  Lungs were incubated at 37˚C 
for 30 minutes and then mashed through a 100 µm cell strainer (Thermo Fisher Scientific; Cat 
#08-771-19).  ACK Lysing Buffer (Thermo Fisher Scientific; Cat #A1049201) was added to the 
single cell suspension and this mixture was spun down at 1,200 RPM for 5 minutes. The ACK 
was washed out with 50 mL of isolation buffer. Isolation buffer consisted of 1 mM EDTA and 2.5% 
FBS in PBS.  
For Mk isolation, a negative selection protocol was used that included biotinylated anti- 
CD11b (BioLegend; Cat #NC0200884), B220 (BioLegend; Cat #NC0200885), CD3 (BioLegend; 
Cat #100304), and CD146 (BioLegend; Cat #134716) antibodies and incubating in a 5 mL 
polystyrene tube (Laboratory Product Sales; Cat #L285601) with 50 µL/mL of rat serum. All 
antibodies were 5 µg/mL final concentration and streptavidin beads (STEMCELL Technologies; 
Cat #19860) at 75 µL/mL of sample (under 1 x 109 cells) concentration added. Each sample was 
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then added to a magnet and incubated for 3-5 minutes and non-bound cells transferred to a 15 
mL tube with pre-warmed complete DMEM.  
Cells from tibias and femurs were isolated by flushing the bone marrow with isolation buffer 
using a 20-gauge needle (BD Biosciences, Cat# 14-826D).  If Mks were used for experimentation, 
the same procedure as the lungs were used for the BM.  For bone marrow derived dendritic cells 
we followed the protocol provided by Abcam (https://www.abcam.com/protocols/bmdc-isolation-
protocol). 
 
Flow cytometry and ImageStream reagents. Anti- CD41 (MWReg30, BioLegend), MHC II 
(M5/114.15.2, BioLegend), CD54 (YN1/1.7.4, BioLegend), CD69 (H1.2F3, BioLegend), Brilliant 
Stain Buffer (BD Biosciences, Cat #BDB563794), CD4 (GK1.5, BioLegend), CD205 (NLDC-145, 
BioLegend), CD207 (4C7, BioLegend), CD8 (53-6.7, BioLegend), CD326 (G8.8, BioLegend), 
CD103 (2E7, BioLegend), CD105 (SN6h, BioLegend), CD252 (RM134L, BioLegend), Ly-6C 
(HK1.4, BioLegend), CD62P (RMP-1, BioLegend), CD3 (17A2, BioLegend), CD86 (GL-1, 
BioLegend), CD19 (MB19-1, BD Bioscience), CD19 (1D3/CD19, BioLegend), CCR7 (4B12, 
BioLegend), Cell Activation Cocktail (without Brefeldin A) (BioLegend, Cat #50-712-273), CD25 
(3C7, BioLegend), OneComp eBeads (Fisher Scientific, Ca t# 50-112-9031), CD11b (M1/70, 
BioLegend), TER-119 (TER-119, BioLegend), Corning™ Falcon™ Round-Bottom Polystyrene 
Tubes (Corning, Cat #352054), H-2Db (KH95, BioLegend), DRAQ5™ Fluorescent Probe Solution 
(Thermo Fisher Scientific, Cat #PI62251), CD45 (PI62251, BioLegend), IFN-γ (XMG1.2, 
BioLegend), and Leukocyte Activation Cocktail, with BD GolgiPlug™ (Fisher Scientific, Cat 
#BDB550583). 
 
Single cell RNA-seq. Cell suspensions were loaded on a Chromium Single-Cell Instrument 
(10x Genomics, Pleasanton, CA, USA) to generate single-cell Gel Bead-in-Emulsions (GEMs). 
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Libraries were prepared using Chromium Single-Cell 3′ Library & Gel Bead Kit (10x Genomics). 
The beads were dissolved and cells were lysed per manufacturer’s recommendations.  GEM 
reverse transcription (GEM-RT) was performed to produce a barcoded, full-length cDNA from 
poly-adenylated mRNA.  After incubation, GEMs were broken and the pooled post-GEM-RT 
reaction mixtures were recovered and cDNA was purified with silane magnetic beads (DynaBeads 
MyOne Silane Beads, PN37002D, ThermoFisher Scientific).  The entire purified post GEM-RT 
product was amplified by PCR. This amplification reaction generated sufficient material to 
construct a 3’ gene expression library.   For 3’ gene expression library, enzymatic fragmentation 
and size selection was used to optimize the cDNA amplicon size and indexed sequencing libraries 
were constructed by End Repair, A-tailing, Adaptor Ligation, and PCR. Final libraries contain the 
P5 and P7 priming sites used in Illumina bridge amplification. Paired-end reads were generated 
for each sample using Illumina’s NextSeq550v2.  
 
Single cell RNA-seq analysis.  Raw sequencing was processed and aligned to the Mus 
musculus genome assembly (mm10) using Cell Ranger software (v3, 10x Genomics). 
Subsequent quality control and secondary analysis steps were carried out using Seurat 
and cells with high mitochondria content (10% of total reads) were removed.  Cells with 
very high RNA or gene content (doublets) were also excluded from downstream analysis. 
Technical variations such as sequencing depth, proportion of mitochondrial transcripts, 
differences in cell cycle states (dividing versus non-dividing) were regressed out during 
data normalization and scaling.  For each sample, cells with similar transcriptomic profiles 
were grouped into specific clusters by a shared nearest neighbor (SNN) modularity 
optimization-based clustering algorithm. We assigned cell type identities to clusters of 
interest based on canonical markers.  
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Sample from all three captures (one from bone marrow, two from lungs) were 
integrated to investigate shared cell states across multiple data sets. Differentially 
expressed genes for identity classes were identified using Wilcoxon rank sum test (Seurat 
FindMarkers default). Markers that are specific to each identity were then submitted to 
enrichR(31, 32) for gene ontology analysis.  
 
Lung Intravital Imaging. Lung imaging was done after oropharyngeal (OP) challenge with LPS 
and intratracheal dosing with DQ-Ova.  Mice were Pf4-Cre Rosa26-LSL-tdTomato.  Evans blue 
dye was used as a blood plasma label.  Imaging started around 30 mins after DQ-OVA delivery 
and continued for approximately 80 mins with each time frame taking around 95 secs to cycle. 
Lung imaging used the set-up procedure two-photon microscopy techniques, and image analysis 
are previously described(2). 
 
Immunohistochemistry.  Lungs were fixed in 60% methanol, 10% acetic acid, 30% H2O solution 
and 5 μM unstained sections produced by standard methodology.  Slides were stained with anti-
CD42c (Emfret Analytics, Cat# M050-0) at a concentration of 1:500 and were counterstained after 
secondary staining with a mouse anti-rat antibody. Macaque lungs were stained with anti-CD41 
(Abcam, Cat# ab63983; DAB brown chromagen) at a concentration of 1:50 on the Leica Bond RX 
auto-staining machine.  
 
Blood collection, Complete Blood Counts (CBCs), Platelet activation, and Plasma 
Isolation.  Complete blood counts (CBC) were performed using an Abaxis VetScan HM5 on 
mouse blood collected in EDTA tubes (VWR, Cat# 95057-293) from a retro-orbital bleed. 
Plasma was isolated from blood spun at 3,000 RPMs for 10 minutes. Plasma not used 
immediately was stored at -20˚C.  Platelets were activated as previously described(17).  
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ELISA.  ELISAs were performed following manufacturer’s instructions. ELISAs included: OVAL 
High Sensitivity ELISA Kit (Chicken) (Aviva Systems Biology, Cat#: OKCD01353), Mouse TNF-
alpha DuoSet ELISA (Fisher Scientific, Cat#: DY41005), Mouse IL-6 DuoSet ELISA (Fisher 
Scientific, Cat#: DY40605), Mouse IL-4 DuoSet ELISA (Fisher Scientific, Cat#: DY40405), Mouse 
IL-2 DuoSet ELISA (Fisher Scientific, Cat#: DY40205), Mouse IL-10 Quantikine ELISA Kit (Fisher 
Scientific, Cat#: M1000B), and Mouse IFN DuoSet ELISA (Fisher Scientific, Cat#: DY485-05). 
The Proteome Profiler Mouse Cytokine Array Kit, Panel A (Fisher Scientific, Cat#: ARY006) was 
used to compare BM and Lung Mk cytokine expression. The methods used for the Cytokine Array 
were provided by the manufacturer. Lippopolysaccaride (LPS) (Sigma-Aldrich, Cat#: L6529-1mg) 
was used as a stimulus in many of the Mk activation experiments.  
 
Oropharyngeal Treatment. Mice were anesthetized with isoflurane and suspended using dental 
floss to allow oral access. The tongue was gently encouraged out of the mouth and held in place 
with a pipette tip to ensure the mouse was unable to swallow. 50 µL of control or treatment was 
delivered into the trachea via a standard lab pipette (20-200 µL). The mouse was held in position 
until the breathing of the mouse returned to normal. 
 
Mk-lineage depletion and IL-33 depletion experiments. Mice were given 4 µg/g of -CD42b or 
the appropriate IgG control during the first day of the experiment. On the following day the mice 
were given Fc-ST2 5 µg/mouse. On D4 the mice were sacrificed. For the IL-33 depletion 
experiments, pups were given either Fc-ST2 or IgG (200 ng/pup) subcutaneous injections within 
hours of birth and again on D4. On D7 the pups were sacrificed with 10 minutes of CO2 and then 
decapitation. After sacrificing mice for each experiment flow cytometry was used for data analysis 
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BM Transfer Experiment. To determine whether the lung environment is one of the mechanisms 
behind the differences in the BM and lung Mks we wanted to see if BM Mks transferred into the 
lung would have an altered phenotype. BM Mks were isolated from naïve WT mice and were 
stained with CellTrace Violet (Thermo Fischer, Cat#: C34557) using the instructions from the 
manufacturer. Three million cells were transferred to naïve WT mice via OP route with either PBS 
or GFP E. Coli. The mice were sacrificed 2 days later for flow cytometry.  
 
E. coli culture and CFU count.  Mice were given either Escherichia coliGFP+ or E. coliGFP+ 
(ATCC: The Global Bioresource Center, Cat# 25922GFP) expressing full length Ovalbumin via 
an oropharyngeal (OP) administration. The ovalbumin plasmid was obtained from AddGene 
(Cat#: 25099). Mice were given 5 x107 E. coli. GFP E. coli.  Mouse weight was monitored daily.  
 
CFU was determined using a plate count protocol. Frozen bacterial stocks were taken from the -
80˚C freezer, after which a 100 µL tip was passed three times through the bacterial stock and 
then the whole tip was added to a flask with LB Broth (Thermo Fisher Scientific, Cat#: BP1427-
500) and 100 mg/mL of ampicillin (Thermo Fisher Scientific, Cat#: BP1760-5). The cells were 
shaken at 37˚C and 200 RPMs for 19 hours. Dilutions of the bacteria were plated on LB nutrient 
agar plates and incubated overnight. At the end of the incubation time the plates that had below 
30 colonies or above 300 colonies were discarded due to concerns about accuracy. Plates with 
colonies between those numbers were counted and the following equation was used to 
determine CFU/mL: 
 
number of colonies (CFUs) = # of bacteria/ml 
dilution X amount plated 
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Data Analysis. ELISAs were quantified using the BMG Fluostar OPTIMA and MyAssays. Flow 
cytometers were an Accuri C6 and BD LSR II. All flow cytometry samples were analyzed by 
FlowJo Version 10.0.7 or Version 8.7. Imagestream data was analyzed using IDEAS. 
 
Statistics. Statistics were performed using GraphPad Prism Version 7. Based on the 
experimental design either a t-test (2-tailed) or One-way ANOVA using Bonferroni’s correction 
were used.  A P-value less than 0.05 was considered significant.  The value of the stars are 
indicated as *P = 0.01 to 0.05, **P = 0.001 to 0.01, ***P = 0.0001 to 0.001, and ****P < 0.0001. 
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Figure Legends  
Figure 1. Lung and BM Mks are phenotypically distinct.  A) Mks are present in the lung.  Lung 
sections from WT mice, TPOR-/- mice, and macaque primates were immunostained with anti-
CD42c antibody.  Mks were noted in WT mouse and primate lungs (representative images).  B) 
BM Mk ploidy is greater than lung Mk.  BM and lung Mk ploidy determined by flow cytometry. C) 
Integration of bone marrow and lung scRNA-seq data. BM Mks and lung Mks had distinct mRNA 
expression patterns. D) Venn diagram and dot plot from scRNA-seq analysis. Venn diagram 
demonstrates common and specific markers for Mks and DCs. Dot plot indicates the average 
expression and proportion of cells expressing genes of interest.  (± SEM; *P<0.05, **0.01, 
***0.001). 
 
Figure 2. Lung and Mk immune molecule expression. A) ImageStream Flow Cytometry 
demonstrated that lung Mks expressed more CD11c and MHC II compared to BM Mks.  
B) Comparison of mouse lung and BM Mk APC related molecule expression by flow cytometry. 
Lung Mks express more APC associated molecules. C) Comparison of primate lung and BM APC 
related molecule expression. Lung Mks express more APC associated molecules. (± SEM; 
*P<0.05, **0.01, ***0.001). 
 
Figure 3. Lung Mk immune phenotype is environmentally regulated. A) MHC II and ICAM1 
expression on Mks from P0 and adult mice.  Neonatal Mks had reduced MHC II and ICAM1 
compared to adult lung Mks.   B) BM Mk phenotype plasticity in vivo. BM Mks were isolated, CFSE 
labeled and OP delivered to control mice. 2 days later transferred BM Mk MHC II and CCR7 were 
determined. BM Transferred BM Mks had increased immune molecule expression in the lung 
environment.  C) BM Mks increased MHC II expression in response to immune stimuli. BM Mks 
were incubated with immune stimuli for 48 hrs and MHC II expression determined.  D) Lung 
derived immune modulatory cytokines induced BM Mk immune differentiation.  BM Mks were 
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incubated with IL-33 or IL-33 in combination with other common lung cytokines. 48 hrs later 
immune differentiation was determined.  E) IL-33 promoted lung Mk immune differentiation in vivo.  
Mice were treated with Mk depleting antibody or control IgG.  Mice were then treated with either 
Fc-ST2 as an IL-33 blocking agent or control IgG. Recovering Mks had increased MHC II that 
was greatly attenuated by IL-33 blocking.  F) P0 mice were treated with IgG or Fc-ST2 and on P7 
MkL immune phenotype determined.  IL-33 blocking reduced post-natal MkL immune 
differentiation.  (± SEM; *P<0.05, **0.01, ***0.001). 
 
Figure 4. Lung Mks Process and Present Antigen.  A-B) Lung Mks had greater LPS induced 
inflammatory molecule production compared to BM Mks.  Mks were incubated for 24 hrs with 
control buffer or LPS. Inflammatory molecules were identified by a A) cytokine array and B) KC in 
the supernatant measured by ELISA.  C) Antigen processing in vitro.  Mks were incubated with 
DQ-Ova for 30 mins and fluorescence was determined by flow cytometry.  D-E) MKs internalize 
antigen in vivo. D) Mice were treated with control buffer or DQ-Ova via an OP route.  80 mins later 
real-time in vivo lung imaging was performed (representative image). E) 24 hrs post DQ-Ova 
lungs were also isolated to quantify fluorescent Mks.  Lung Mks internalized antigen.  F) Lung 
Mks are more phagocytic than BM Mks.  BM and lung Mks were incubated with control buffer or 
GFP-E Coli and 30 mins later fluorescence was determined by ImageStream (representative 
images).  G) Lung Mks take up E. coli in vivo. E. coli was delivered via OP route and 3 hrs later 
E. coli positive lung Mks and DCs were quantified by flow cytometry.  (± SEM; *P<0.05, **0.01, 
***0.001) 
 
Figure 5.  Lung Mks Present Antigen to T Cells.  A) Lung Mks activated OTII T cells in vitro. T 
cells were co-cultured with lung Mks or splenocytes and on d3 T cell activation was determined.  
B) Mice lacking Mks had reduced antigen specific T cell responses in vivo. WT and TPOR-/- mice 
were given OTII T cells and 24 hrs later mice were OP treated with E. coliOVA.  OTII T cell activation 
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was determined on d3. WT, but not TPOR-/- mice, had OTII T cell activation in the lungs and 
reduced OTII T cell activation in mLN.  C-D) Lung Mks present antigen in the context of MHC II 
in vitro.  WT and MHC II-/- lung Mks were incubated with OTII T cells and Ova/LPS. On d3 T cell 
activation was determined by flow cytometry.  C) WT lung Mks induced more T cell activation than 
did MHC II-/- lung Mks on d3 and D) more IL-2 production on d8.  E) MkL present antigen in the 
context of MHC II in vivo. WT and Mk specific MHC II-/- mice were given OTII T cells and Ova/LPS 
via an OP route.  On d3 OTII T cell activation was determined by flow cytometry. WT mice had 
more CD25 positive OTII cells and OTII T cell proliferation compared to Mk-MHC II-/- mice.  (± 
SEM; *P<0.05, **0.01, ***0.001) 
 
 
 
 
 
